177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial – LANCET

Morris, MJ; Castellano, D; Herrmann, K; de Bono, JS; Shore, ND; Chi, KN; Crosby, M; Piulats, JM; Fléchon, A; Wei, XX; Mahammedi, H; Roubaud, G; Studentová, H; Nagarajah, J; Mellado, B; Montesa-Pino, A; Kpamegan, E; Ghebremariam, S; Kreisl, TN; Wilke, C; Lehnhoff, K;...

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial – LANCET

Pérez-García, JM; Cortés, J; Ruiz-Borrego, M; Colleoni, M; Stradella, A; Bermejo, B; Dalenc, F; Escrivá-de-Romaní, S; Martínez, LC; Ribelles, N; Marmé, F; Cortés, A; Albacar, C; Gebhart, G; Prat, A; Kerrou, K; Schmid, P; Braga, S; Di Cosimo, S; Gion, M; Antonarelli,...